SHR-1210 (camrelizumab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SHR-1210 (camrelizumab), covering 2025-07-04 to 2025-07-04. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer [Phase 2]